Optimisation of Prime-boost Immunization in Mice Using Novel Protein-based and Recombinant Vaccinia (Tiantan)-based HBV Vaccine

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2012 Sep 13

PMID 22970140

Citations 11

Authors

Hong Chen

Xia Chuai

Yao Deng

Bo Wen

Wen Wang

Shaoqing Xiong

Li Ruan

Wenjie Tan

Affiliations

Soon will be listed here.

Abstract

Background: A therapeutic vaccine for chronic hepatitis B virus (HBV) infection that enhances virus-specific cellular immune responses is urgently needed. The "prime-boost" regimen is a widely used vaccine strategy against many persistence infections. However, few reports have addressed this strategy applying for HBV therapeutic vaccine development.

Methodology/principal Findings: To develop an effective HBV therapeutic vaccine, we constructed a recombinant vaccinia virus (Tiantan) containing the S+PreS1 fusion antigen (RVJSS1) combined with the HBV particle-like subunit vaccine HBVSS1 to explore the most effective prime-boost regimen against HBV. The immune responses to different prime-boost regimens were assessed in C57BL/C mice by ELISA, ELISpot assay and Intracellular cytokine staining analysis. Among the combinations tested, an HBV protein particle vaccine priming and recombinant vaccinia virus boosting strategy accelerated specific seroconversion and produced high antibody (anti-PreS1, anti-S antibody) titres as well as the strongest multi-antigen (PreS1, and S)-specific cellular immune response. HBSS1 protein prime/RVJSS1 boost immunization was also generated more significant level of both CD4+ and CD8+ T cell responses for Th1 cytokines (TNF-α and IFN-γ).

Conclusions: The HBSS1 protein-vaccine prime plus RVJSS1 vector boost elicits specific antibody as well as CD4 and CD8 cells secreting Th1-like cytokines, and these immune responses may be important parameters for the future HBV therapeutic vaccines.

Citing Articles

Immunogenicity of a vaccinia virus-based severe acute respiratory syndrome coronavirus 2 vaccine candidate.

Mei S, Fan Z, Liu X, Zhao F, Huang Y, Wei L Front Immunol. 2022; 13:911164.

PMID: 35935962 PMC: 9353262. DOI: 10.3389/fimmu.2022.911164.

Improving Therapeutic Vaccination against Hepatitis B-Insights from Preclinical Models of Immune Therapy against Persistent Hepatitis B Virus Infection.

Knolle P, Huang L, Kosinska A, Wohlleber D, Protzer U Vaccines (Basel). 2021; 9(11).

PMID: 34835264 PMC: 8623083. DOI: 10.3390/vaccines9111333.

Manganese salts function as potent adjuvants.

Zhang R, Wang C, Guan Y, Wei X, Sha M, Yi M Cell Mol Immunol. 2021; 18(5):1222-1234.

PMID: 33767434 PMC: 8093200. DOI: 10.1038/s41423-021-00669-w.

Comprehensive Analysis of the Safety Profile of a Single-Stranded RNA Nano-Structure Adjuvant.

Park H, Ko H, Won D, Hwang D, Shin Y, Kwak H Pharmaceutics. 2019; 11(9).

PMID: 31500241 PMC: 6781302. DOI: 10.3390/pharmaceutics11090464.

Protective Efficacy of the Conserved NP, PB1, and M1 Proteins as Immunogens in DNA- and Vaccinia Virus-Based Universal Influenza A Virus Vaccines in Mice.

Wang W, Li R, Deng Y, Lu N, Chen H, Meng X Clin Vaccine Immunol. 2015; 22(6):618-30.

PMID: 25834017 PMC: 4446406. DOI: 10.1128/CVI.00091-15.

References

Bertoletti A, Gehring A . Therapeutic vaccination and novel strategies to treat chronic HBV infection. Expert Rev Gastroenterol Hepatol. 2009; 3(5):561-9. DOI: 10.1586/egh.09.48. View

Radcliffe J, Roddick J, Friedmann P, Stevenson F, Thirdborough S . Prime-boost with alternating DNA vaccines designed to engage different antigen presentation pathways generates high frequencies of peptide-specific CD8+ T cells. J Immunol. 2006; 177(10):6626-33. DOI: 10.4049/jimmunol.177.10.6626. View

Zhou Y, Wu C, Zhuang H . Vaccination against hepatitis B: the Chinese experience. Chin Med J (Engl). 2009; 122(1):98-102. View

Hutchings C, Gilbert S, Hill A, Moore A . Novel protein and poxvirus-based vaccine combinations for simultaneous induction of humoral and cell-mediated immunity. J Immunol. 2005; 175(1):599-606. DOI: 10.4049/jimmunol.175.1.599. View

Chisari F, Isogawa M, Wieland S . Pathogenesis of hepatitis B virus infection. Pathol Biol (Paris). 2010; 58(4):258-66. PMC: 2888709. DOI: 10.1016/j.patbio.2009.11.001. View

Chen H, Wen B, Deng Y, Wang W, Yin X, Guan J . Enhanced effect of DNA immunization plus in vivo electroporation with a combination of hepatitis B virus core-PreS1 and S-PreS1 plasmids. Clin Vaccine Immunol. 2011; 18(11):1789-95. PMC: 3209024. DOI: 10.1128/CVI.05113-11. View

Gu S, Huang T, Miao Y, Ruan L, Zhao Y, Han C . A preliminary study on the immunogenicity in rabbits and in human volunteers of a recombinant vaccinia virus expressing Epstein-Barr virus membrane antigen. Chin Med Sci J. 1991; 6(4):241-3. View

Liu M . Gene-based vaccines: Recent developments. Curr Opin Mol Ther. 2010; 12(1):86-93. View

Yang S, Lee C, Park S, Im S, Kim Y, Son J . Correlation of antiviral T-cell responses with suppression of viral rebound in chronic hepatitis B carriers: a proof-of-concept study. Gene Ther. 2006; 13(14):1110-7. DOI: 10.1038/sj.gt.3302751. View

10.

Maeng C, Ryu C, Gripon P, Guguen-Guillouzo C, Hong H . Fine mapping of virus-neutralizing epitopes on hepatitis B virus PreS1. Virology. 2000; 270(1):9-16. DOI: 10.1006/viro.2000.0250. View

11.

Sjogren M . Prevention of hepatitis B in nonresponders to initial hepatitis B virus vaccination. Am J Med. 2005; 118 Suppl 10A:34S-39S. DOI: 10.1016/j.amjmed.2005.07.012. View

12.

Cresswell P, Ackerman A, Giodini A, Peaper D, Wearsch P . Mechanisms of MHC class I-restricted antigen processing and cross-presentation. Immunol Rev. 2005; 207:145-57. DOI: 10.1111/j.0105-2896.2005.00316.x. View

13.

Wen Y, Wu X, Hu D, Zhang Q, Guo S . Hepatitis B vaccine and anti-HBs complex as approach for vaccine therapy. Lancet. 1995; 345(8964):1575-6. DOI: 10.1016/s0140-6736(95)91126-x. View

14.

Qiao M, Macnaughton T, Gowans E . Adsorption and penetration of hepatitis B virus in a nonpermissive cell line. Virology. 1994; 201(2):356-63. DOI: 10.1006/viro.1994.1301. View

15.

Chisari F . Cytotoxic T cells and viral hepatitis. J Clin Invest. 1997; 99(7):1472-7. PMC: 507965. DOI: 10.1172/JCI119308. View

16.

Hemachandra A, Puls R, Sirivichayakul S, Kerr S, Thantiworasit P, Ubolyam S . An HIV-1 clade A/E DNA prime, recombinant fowlpox virus boost vaccine is safe, but non-immunogenic in a randomized phase I/IIa trial in Thai volunteers at low risk of HIV infection. Hum Vaccin. 2010; 6(10):835-40. PMC: 3322532. DOI: 10.4161/hv.6.10.12635. View

17.

Bremer C, Sominskaya I, Skrastina D, Pumpens P, Abd El Wahed A, Beutling U . N-terminal myristoylation-dependent masking of neutralizing epitopes in the preS1 attachment site of hepatitis B virus. J Hepatol. 2010; 55(1):29-37. DOI: 10.1016/j.jhep.2010.10.019. View

18.

Horiike N, Fazle Akbar S, Michitaka K, Joukou K, Yamamoto K, Kojima N . In vivo immunization by vaccine therapy following virus suppression by lamivudine: a novel approach for treating patients with chronic hepatitis B. J Clin Virol. 2005; 32(2):156-61. DOI: 10.1016/j.jcv.2004.07.004. View

19.

Janssen H, van Zonneveld M, Senturk H, Zeuzem S, Akarca U, Cakaloglu Y . Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet. 2005; 365(9454):123-9. DOI: 10.1016/S0140-6736(05)17701-0. View

20.

Michel M, Tiollais P . Hepatitis B vaccines: protective efficacy and therapeutic potential. Pathol Biol (Paris). 2010; 58(4):288-95. DOI: 10.1016/j.patbio.2010.01.006. View